Dengue Vaccine Shows Promise Against 3 Out of 4 Viruses
This article is for subscribers only.
The most advanced experimental vaccine against dengue protected some children against the disease in a study, though a more effective weapon may still be needed to curb the most widespread mosquito-borne infection.
In a clinical trial involving more than 10,000 children in Southeast Asia, the vaccine reduced the risk of infection by 56.5 percent, and the chance of severe complications by 88.5 percent, according to findings published today in The Lancet medical journal. The inoculation was less effective among the youngest children who are most in danger of contracting dengue, and failed to protect against one of four viruses that cause it.